^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Mvasi (bevacizumab-awwb) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/15/2018
Excerpt:
Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer.
Secondary therapy:
paclitaxel
